News

Cancer stem cells caught
Enlarge image

ScienceBelgiumUK

Cancer stem cells caught

06.08.2012 - Belgian and UK researchers have for the first time tracked the existence of cancer stem cells in vivo. The study provides another piece of evidence that cancer stem cells are drivers of tumour recurrence.

The study published in Nature demonstrates for the first time the existence of cancer stem cells during unperturbed solid tumour growth. The team led by Cédric Blanpain from Université libre de Bruxelles found specific subsets of cells in mouse tumours that seem to be responsible for the re-growth of tumours. These findings shed new light on the controversial issue of whether cancer stem cells exist in growing tumours and may have implications for potential therapies.

Cancer stem cells are proposed to be responsible for tumour recurrence after anti-cancer treatments fail. However, evidence for cancer stem cells in solid tumours remained unproven so far. Blanpain and co-workers tracked tumour progression in mouse model of skin cancer and observe a persistent subpopulation of tumour cells with stem-like properties. There are two more groups publishing in parallel on their tracking success of cancer stem cells in Nature and Science.

http://www.european-biotechnology-news.com/news/news/2012-03/cancer-stem-cells-caught.html

BusinessSwitzerland

03.07.2015 Biotech giant Biogen is investing CHF 1bn in a new pharmaceutical production plant in the Swiss town of Luterbach. Noted as one of the world’s oldest biotech firms, the new plant will create up to 400 jobs.

Personalised MedicineNetherlandsBelgiumSpain

02.07.2015 Dutch biotech Amarna and Austrian Biomarker research centre CBmed have joined forces to develop several immunotherapies, including therapies against cancer and diabetes type 2. The joint venture will develop Amarna’s next generation viral vector platform.

M&ASwitzerland

30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.

Personalised MedicineGermany

25.06.2015 German immunotherapy expert BioNTech AG has partnered up with Europe’s largest engineering company Siemens to construct a manufacturing site for BioNTech’s personalised cancer vaccine.

Bioelectronic researchSweden

24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.

FinancingLuxembourgItalySwitzerland

23.06.2015 Cosmo Pharmaceuticals is floating its majority-owned subsidiary Cassiopea at the Swiss Stock Exchange, with the aim to raise between CHF150m and CHF200m.

EventEUGermany

22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.

EventEU

17.06.2015 At the BIO convention in Philadelphia, the biotech industry celebrates new gene and cell therapies, and hails its unlikely superheroes.

ResearchUKSwitzerland

16.06.2015 Northern Ireland’s biopharma Almac Discovery is partnering up with Roche subsidiary Genentech in a two-year joint research programme to discover and develop cancer treatments.

M&ANorwayFinlandSweden

12.06.2015 The high-potential cancer immunotherapy market is fiercely fought, and small companies have trouble making their mark. Nordic companies Targovax and Oncos have joined forces to create a Nordic immuno-oncology champion named Polaris.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BAVARIAN NORDIC (D)44.62 EUR12.34%
  • MOLOGEN (D)5.20 EUR7.00%
  • BRITISH TECHNOLOGY GROUP (UK)686.00 GBP6.94%

FLOP

  • CYTOS (CH)0.50 CHF-9.09%
  • NOVACYT (F)4.99 EUR-6.90%
  • EPIGENOMICS (D)5.12 EUR-5.19%

TOP

  • DBV Technologies (F)54.26 EUR20.3%
  • Allergy Therapeutics (UK)23.50 GBP15.3%
  • BIOINVENT INTERNATIONAL AB (S)2.58 SEK13.7%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • TRANSGENE (F)3.80 EUR-26.5%
  • NORDIC NANOVECTOR (N)25.50 NOK-25.7%

TOP

  • 4SC (D)4.90 EUR375.7%
  • ADOCIA (F)66.29 EUR341.9%
  • VERONA PHARMA (UK)5.10 GBP314.6%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • ACTIVE BIOTECH (S)9.00 SEK-70.1%
  • NEOVACS (F)1.14 EUR-68.2%

No liability assumed, Date: 03.07.2015